

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

The effect of Entonox on normal vaginal delivery labor and maternal hemodynamic changes and fetal apgar

Protocol summary

mtmoradi@skums.ac.ir

Summary

This study is done to investigate the effect of Entonox on normal vaginal delivery labor and maternal hemodynamic changes and fetal apgar. Sixteen women candidate for normal vaginal delivery, having the inclusion criteria, will be randomly divided into 2 groups. The intervention group will receive Entonox gas while control group will not. After the active phase of delivery mothers in intervention group will receive Entonox through masks and it will be continue till the second stage. The mean of the pain and maternal hemodynamic changes during the Entonox receiving and the fetal apgar after the birth will be evaluated and will be compared with control group.

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Shahrekord university of medical sciences

Expected recruitment start date

2012-06-06, 1391/03/17

Expected recruitment end date

2012-08-18, 1391/05/28

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201105176480N2**

Registration date: **2012-06-13, 1391/03/24**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-06-13, 1391/03/24

Registrant information

Name

Mohammad Taghi Moradi

Name of organization / entity

Shahrekord University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 38 1334 9509

Email address

Scientific title

The effect of Entonox on normal vaginal delivery labor and maternal hemodynamic changes and fetal apgar

Public title

Investigating the effect of Entonox on normal vaginal delivery labor and maternal hemodynamic changes and fetal apgar

Purpose

Supportive

Inclusion/Exclusion criteria

Inclusion criteria: primiparous women; pregnancy age of 38-42; non twin pregnancy with the cephalic view; being in the early active phase of delivery; having normal fetal heart pattern; weight between 60-80 Kgr. Exclusion criteria: having cardio and other internal disease.

Age

No age limit

Gender

Female

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 60

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Shahrekord university of medical sciences

Street address

Kashani Blvd.

City

Sahrekord

Postal code

Approval date

2009-05-28, 1388/03/07

Ethics committee reference number

88-3-7

Health conditions studied

1

Description of health condition studied

labor

ICD-10 code

O80

ICD-10 code description

Single spontaneous delivery

Primary outcomes

1

Description

labor

Timepoint

one hour

Method of measurement

NSR digital proportional measurement

2

Description

maternal respiration rate

Timepoint

one hour

Method of measurement

numeration

3

Description

maternal blood pressure

Timepoint

one hour

Method of measurement

mercurial manometer

4

Description

maternal heart rate

Timepoint

one hour

Method of measurement

using a device

Secondary outcomes

1

Description

baby apgar

Timepoint

one and five minutes after the birth

Method of measurement

related questionnaire

2

Description

nausea and vomiting

Timepoint

during the delivery

Method of measurement

observation

Intervention groups

1

Description

After starting the delivery active phase (dilatation 4 cm), the intervention group will receive Entonox, with feeling the pain, mothers start to inspiration the gas, with vanishing the pain mothers stop inspiration. They will receive Entonox till the end of the second stage.

Category

Prevention

2

Description

The control group will receive oxygen gas after starting the delivery active phase (dilatation 4cm).

Category
Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center
Hajar hospital
Full name of responsible person
Dr. Sheida Shabanian
Street address
Parastar street
City
Shahrekord

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Vice chancellor for research, Shahrekord university of medical sciences
Full name of responsible person
Dr. Mahmoud Mobasheri
Street address
Kashani Blvd
City
Shahrekord
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice chancellor for research, Shahrekord university of medical sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
Hajar hospital
Full name of responsible person
Dr lobat Jafarzade
Position

Physician of obstetrics and gynecology
Other areas of specialty/work
Street address
Hajar hospital,Hajar street
City
Shahrekord
Postal code
Phone
+98 38 1222 0016
Fax
Email
sheidashabanian@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Hajar hospital
Full name of responsible person
Dr Sheida Shabanian
Position
Physician of obstetrics and gynecology
Other areas of specialty/work
Street address
obstetrics and gynecology department, Hajar hospital, Hajar street
City
Shahrekord
Postal code
Phone
+98 38 1222 0016
Fax
Email
sheidashabanian@yahoo.com
Web page address

Person responsible for updating data

Contact

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty